Gilead Sciences (GILD) Tops Q3 EPS by 51c; raises guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $89.94 +0.07%
Revenue Growth %: +0.8%
Financial Fact:
Shares used in per share calculation - basic: 1.32B
Today's EPS Names:
EMMS, CMTL, LOOP, More
Revenue Growth %: +0.8%
Financial Fact:
Shares used in per share calculation - basic: 1.32B
Today's EPS Names:
EMMS, CMTL, LOOP, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $2.02, $0.51 better than the analyst estimate of $1.51. Revenue for the quarter came in at $7.54 billion versus the consensus estimate of $7.01 billion.
GUIDANCE:
Gilead Sciences sees FY2024 EPS of $4.25-$4.45, versus the consensus of $3.81.
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Educational Development (EDUC) Misses Q3 EPS by 42c
- Alnylam Pharma (ALNY) Announces Preliminary Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance
- Sarepta Therapeutics (SRPT) Reports Preliminary Fourth Quarter and Full-Year 2024 Net Product Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
